author-photo

Begoña Jiménez

Institute of Cancer Research

19

Papers

258

Citations

Citation Trend

Filter By

Papers (15) Sort By

Journal Conference Others

A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study

2019 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (19)
High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy

2017 Oncotarget
Show All
- Source
- Cite
- Save
Citations (3)
Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?

2016 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (11)
Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials

2015 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (27)
Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials

2015 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (21)
Pivotal role of sphingomyelin synthase (SGMS) expression and activity in glioma patient survival presents a potential therapeutic target.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Thrombosis in a population of phase I trial patients.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
468PPHASE I MULTICENTRE TAX-TORC TRIAL OF THE DUAL MTORC1/2 INHIBITOR AZD2014 (A) PLUS WEEKLY PACLITAXEL (P) IN PATIENTS (PTS) WITH SOLID TUMOURS (CRUKD/12/013)

2014 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Complications of hyperglycemia in phase 1 trials targeting the PI3K-akt-mTOR (PAM) pathway.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients

2013 Oral Oncology
Show All
- Source
- Cite
- Save
Citations (33)